All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

HPLC method for determination of enantiomeric purity of a novel respiratory fluoroquinolone: WCK 1152

Author(s): RD Yeole, SV Lawand, SB Bhavsar, PK Deshpande
Wockhardt Research Center, D-4, MIDC, Chikalthana, Aurangabad-431 210, India

Correspondence Address:
R D Yeole Wockhardt Research Center, D-4, MIDC, Chikalthana, Aurangabad-431 210 India E-mail: [email protected]


A sensitive, simple, specific, precise, accurate and rugged method for determination of enantiomeric purity of S-(-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-{4-amino-3,3-dimethylpiperidin-1-yl}-4-oxo-quinoline-3-carboxylic acid hydrochloride monohydrate, WCK 1152, a new drug substance has been developed. The method is based on prederivatization of analyte to diastereomer followed by RP-HPLC using endcapped C-18 stationary phase. Column was maintained at 30°C. The UV/Vis detector was operated at 290 nm. Flow rate of the mobile phase was 1.25 ml/min. The method offers excellent separation of two enantiomers with resolution more than 4 and tailing factor less than 1.5. The method was validated for the quantification of R-(+)-enantiomer impurity, WCK 1153 in the bulk drug. Calibration curves showed excellent linearity over the concentration range of 0.1 to 1.5 mg/ml for WCK 1152 and 0.01 to 0.15 mg/ml for WCK 1153. Precision of the method was 1.13%. Limit of detection and limit of quantitation of the method for WCK 1152 were 0.0006 mg/ml and 0.0018 mg/ml and for WCK 1153 were 0.0007 mg/ml and 0.0021 mg/ml, respectively. Average recovery of the WCK 1153 in WCK 1152 was 94.4%. This method was employed in determining enantiomeric purity of clinical trial batches of WCK 1152.

Full-Text | PDF

 
 
List of Supporting Conferences